In this issue:
Studying the MRTX1133 compound
Efficacy of Gem-Nab and Gem-Ox
Association between FP and PC
Comparing NALIRIFOX and nabpaclitaxel-gemcitabine
Impacts of PERT and NS in mPC patients
Evaluating CA19-9 levels
Moderately hypofractionated IMRT in resectable PC patients
Evaluating first-line palliative chemotherapy regimens
CPI-613 versus curative surgery
Tolerability of nab-paclitaxel plus gemcitabine
Please login below to download this issue (PDF)